CAS 149647-78-9 Vorinostat | Products & Prices & Suppliersts
It is the first HDAC inhibitor approved by the US Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma (CTCL) with significant skin involvement that is still progressing, resistant or relapsing after two systemic regimens. On October 6, 2006, the US Food and Drug Administration (FDA) have approved vorinostat capsules (vorinostat) for the treatment of skin cancer drugs. The drug is the first novel type of anti-cancer drugs of histone deacetylase inhibitor devel.
ldentification
- Cas NO.: 149647-78-9
- CID: 5311
- Mw: 264.3202
- MF: C14H20N2O3
- Name:Vorinostat (Related Reference)
- Synonyms: CS-1949; M344; N-Hydroxy-N'-phenyloctanediamide; Octanediamide, N1-hydroxy-N8-phenyl-; Octanediamide, N-hydroxy-N-phenyl-; SAHA; SAHA cpd; SAHA, N-Hydroxy-Nphenyloctanediamide, Zolinza;
- EINECS: 1308068-626-2
Safety Data
- [Risk Codes]
- [Safety Statements]
- Hazard Symbols:
Properties
-
- Appearance:White Crystalline Solid
- Molecular Weight:264.3202
- Density:1.174
- Boiling Point:°Cat760mmHg
- Melting Point:161-162°C
- Flash Point:°C
- Storage Temperature:-20°C
- Refractive index:1.566
- Solubility:Soluble in ethanol (0.25 mg/ml), DMSO & DMF (20 mg/ml)
- More Properties>>